State Street’s Regencell Bioscience RGC Stock Holding History

State Street’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$301K	Buy	+11,851	New	+$335K	﹤0.01%	3782

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State Street's RGC Position: Q1 2026 in Review

State Street opened a new position in Regencell Bioscience (RGC) in Q1 2026: 11,851 shares worth $301K. The stake represents ﹤0.01% of the portfolio and ranks #3782 among its holdings.

31 funds tracked by Wall St. Rank hold RGC as of Q1 2026.

State Street held 11,851 shares of Regencell Bioscience worth $301K as of Q1 2026.
Regencell Bioscience was a new State Street position in Q1 2026.
Regencell Bioscience made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3782 holding.
31 funds tracked by Wall St. Rank held Regencell Bioscience as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.